QUEBEC CITY, QUEBEC--(CCNMatthews - Oct. 7, 2005) - Emerillon Therapeutics Inc. and HemaX Genome Inc. announced today during BioContact Quebec 2005 that they have signed on September 23rd a definitive purchase agreement whereby Emerillon will acquire all the outstanding shares of HemaX. The merger will create a leading target discovery company, combining Emerillon's drug discovery programs in neurology, pain, asthma and atherosclerosis with those of HemaX in hematopoiesis and immunological disorders.
